Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?Drug development can be quite a risky business at the best of times, but particularly in the biotech Share XBiotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?https://pharmaphorum.com/views-and-analysis/biotech-in-post-brexit-britain-the-future-for-the-uks-pharma-innovation-engine/
Changing heartsDanish biotech Acesion Pharma is hoping to change the standard of care in atrial fibrillation. Richard Staines spoke Share XChanging heartshttps://pharmaphorum.com/views-and-analysis/changing-hearts/
The happiness factorAs part of pharmaphorum’s Eye on Innovation series, Richard Staines spoke to John Zibert, chief medical officer at Share XThe happiness factorhttps://pharmaphorum.com/r-d/views-analysis-r-d/happiness-factor-dermatological-conditions/
R&D roundup: the ups and downs of CRISPR and Alzheimer’sWhile the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm Share XR&D roundup: the ups and downs of CRISPR and Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/
What will a no-deal Brexit mean for pharma and healthcare?Britons are bracing themselves for the UK’s imminent departure from the European Union. A worst-case scenario would see Share XWhat will a no-deal Brexit mean for pharma and healthcare?https://pharmaphorum.com/views-and-analysis/what-will-a-no-deal-brexit-mean-for-pharma-and-healthcare/
Inspiring a new generation of women in pharmaAs part of a series of articles highlighting the role of women in the pharma industry, Richard Staines Share XInspiring a new generation of women in pharmahttps://pharmaphorum.com/views-and-analysis/inspiring-a-new-generation-of-women-in-pharma/
Taking plasma from donor to patientLutz Bonacker from CSL Behring tells us about the unique aspects of working with plasma-derived medicines and how Share XTaking plasma from donor to patienthttps://pharmaphorum.com/views-and-analysis/taking-plasma-from-donor-to-patient/
Opening doors in pharmaceutical developmentEvidera surveys the adoption of machine learning by the pharmaceutical industry and looks at how it can increase Share XOpening doors in pharmaceutical developmenthttps://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/machine-learning-opening-doors-in-pharmaceutical-development/
Women in Science: AstraZenecaWe speak to three of AstraZeneca’s senior leaders about their careers, the future of their therapy areas and Share XWomen in Science: AstraZenecahttps://pharmaphorum.com/r-d/views-analysis-r-d/women-in-science-astrazeneca/
